Pharmaceutical News

RSS

WADA, IOC compliant safe alternatives to dangerous and illegal anabolic steroids

SteroidAlternatives.com has launched a cutting-edge line of legal, powerful, and safe alternatives to dangerous and illegal anabolic steroids. All products offered by SteroidAlternatives.com are WADA (World Anti-Doping Agency) and IOC (International Olympic Committee) compliant. This line of products is effective and offers the consumer a legal way to build superior muscle, strength, and speed without having to resort to taking harmful, illegal substances.

9 Mar 2010

Pharmaceutical Institute announces the release of Therapeutic Area Essentials

Pharmaceutical Institute, a leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, today announced the release of Therapeutic Area Essentials™, a comprehensive suite of more than 155 therapeutic area e-courses covering diagnosis, cause, and treatment for over 40 disease states.

9 Mar 2010

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.

9 Mar 2010

FDA invites "Little Women" to present research on dangers of HPV vaccines

Called the "Little Women," six women who have spent the past three years listening, documenting and researching parental concerns about Gardasil have been invited to formally present their information to the FDA on March 12. FDA participants include the Office of Communication, Outreach and Development/Center of Biologics (CBER), Office of Biostatistics and Epidemiology, and Office of Vaccines Research and Review.

9 Mar 2010

State Roundup: N.Y. drug pricing, Vermont hospital ads, Massachusetts nursing homes and anti-psychotics

Poughkeepsie Journal: A new report on New York drug prices, "issued by the New York Public Interest Research Group, Consumers Union, the Center for Medical Consumers and AARP, looked at the price of the 10 most popular drugs found in the state's pharmacies provided through a Freedom of Information Law request. The analysis found a drastic price difference in the same drugs offered in different locations" (Campbell, 3/6).

9 Mar 2010

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.

9 Mar 2010

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Some anti-depressant drugs are associated with an increased chance of developing cataracts, according to a new statistical study by researchers at the University of British Columbia, Vancouver Coastal Health Research Institute and McGill University.

9 Mar 2010

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.

9 Mar 2010

MDS ends strategic repositioning with divestiture of MDS Pharma Services Early Stage business

MDS Inc., a leading provider of products and services to the global health sciences markets, today announced that it has completed the divestiture of its MDS Pharma Services Early Stage business.

9 Mar 2010

Usage of gonadotropins in assisted reproductive technologies significantly improves outcomes

The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, "Gonadotropins in the Treatment of Infertility" by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals. The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.

9 Mar 2010

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic’s proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.

9 Mar 2010

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

The Society for Biomolecular Sciences will honor three researchers for their substantial contributions to the field of drug discovery. Each recipient will accept their award and speak at the SBS 16th Annual Conference & Exhibition in Phoenix, Arizona, April 11-15, 2010.

9 Mar 2010

Watson Laboratories sued over ANDA filing for generic Opana ER

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.

9 Mar 2010

Research reveals link between repeated anaesthesia and memory impairment

There is a link between repeated anaesthesia in children and memory impairment, though physical activity can help to form new cells that improve memory, reveals new research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

Prostate-specific dietary supplements should not be taken during radiation therapy treatments because they have been shown to increase the radiosensitivity of normal prostate cell lines, leading to normal tissue complications, according to a study in the March issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.

8 Mar 2010

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

Taro Pharmaceutical Industries Ltd. today reported that it received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Fluorouracil Topical Cream USP, 5%.

8 Mar 2010

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX™ is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers.

8 Mar 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

8 Mar 2010

New nutrition product to address effects of Glycation

After an extensive on going research program, Mineral BioSciences LLC a division of Global Organics Group is proud to announce the introduction of TOTALA® Nutrients, an ingredient that promises to have a profound effect on the nutrition industry.

8 Mar 2010

Pharmaceutical News

WADA, IOC compliant safe alternatives to dangerous and illegal anabolic steroids

Pharmaceutical Institute announces the release of Therapeutic Area Essentials

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

FDA invites "Little Women" to present research on dangers of HPV vaccines

State Roundup: N.Y. drug pricing, Vermont hospital ads, Massachusetts nursing homes and anti-psychotics

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

MDS ends strategic repositioning with divestiture of MDS Pharma Services Early Stage business

Usage of gonadotropins in assisted reproductive technologies significantly improves outcomes

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

Watson Laboratories sued over ANDA filing for generic Opana ER

Research reveals link between repeated anaesthesia and memory impairment

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

New nutrition product to address effects of Glycation

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News